COST-EFFECTIVENESS OF SECOND-LINE VASOPRESSORS FOR THE TREATMENT OF SEPTIC SHOCK

被引：0
|
作者：
Lam, Simon [1 ]
Barreto, Erin [2 ]
Scott, Rachael [3 ]
Kashani, Kianoush [3 ]
Khanna, Ashish [4 ]
Bauer, Seth [5 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] St Marys Hosp, Mayo Clin, Rochester, MN USA
[3] Mayo Clin, Rochester, MN USA
[4] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
[5] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
来源：
CRITICAL CARE MEDICINE | 2020年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
1630
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia
    Whalen, John
    Stillman, Ipek
    Ambavane, Apoorva
    Felber, Eugene
    Makenbaeva, Dinara
    Bolinder, Bjorn
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (05) : 445 - 461
  • [22] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH LENVATINIB FOR THE TREATMENT OF ADVANCED SECOND-LINE ENDOMETRIAL CANCER
    Yfantopoulos, N.
    Gountas, I
    Skroumpelos, A.
    Theiakos, K.
    Economou, O.
    Karokis, A.
    VALUE IN HEALTH, 2024, 27 (12) : S113 - S113
  • [23] Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma
    Zhang, Peng-Fei
    Xie, Dan
    Li, Qiu
    FUTURE ONCOLOGY, 2020, 16 (17) : 1189 - 1198
  • [24] Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain
    G. Villa
    L. J. Hernández-Pastor
    M. Guix
    J. Lavernia
    M. Cuesta
    Clinical and Translational Oncology, 2015, 17 : 24 - 33
  • [25] Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain
    Villa, G.
    Hernandez-Pastor, L. J.
    Guix, M.
    Lavernia, J.
    Cuesta, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (01): : 24 - 33
  • [26] Does first-line treatment impact the cost-effectiveness of second-line treatment for elderly metastatic colon cancer patients?
    Mullins, C. Daniel
    Woldemichael, Andinet
    Zheng, Zhiyuan
    Onukwugha, Ebere
    Seal, Brian S.
    Hanna, Nader
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [27] Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer
    Lam, Simon W.
    Wai, Maya
    Lau, Jessica E.
    McNamara, Michael
    Earl, Marc
    Udeh, Belinda
    PHARMACOTHERAPY, 2017, 37 (01): : 94 - 103
  • [28] Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma
    Liao, Weiting
    Huang, Jiaxing
    Hutton, David
    Zhu, Guiqi
    Wu, Qiuji
    Wen, Feng
    Bai, Liangliang
    Li, Qiu
    LIVER INTERNATIONAL, 2019, 39 (12) : 2408 - 2416
  • [29] Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma
    Giuliani, Jacopo
    Bonetti, Andrea
    CLINICAL GENITOURINARY CANCER, 2019, 17 (02) : E258 - E262
  • [30] Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis
    Dowdy, D. W.
    van't Hoog, A.
    Shah, M.
    Cobelens, F.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2014, 18 (06) : 647 - 654
12345